Hospital CFOs prefer higher prices
How Theo Mastropolos designs MedTech successes backwards
Intro
Hospital CFOs sometimes prefer a higher-priced device.
That sounds counterintuitive, but in medtech it can be exactly right. Theo Mastropolos, CEO of Pleo Flow, told me that when a hospital understands the revenue logic of a device, a higher price can actually make the product more attractive.
Why?
Because the CFO is not just looking at cost.
They are looking at grosss margin, reimbursement fit, and top-line revenue.
Higher price devices increase top-line revenue and gross margins.
If a device helps the hospital generate more revenue dollars within the healthcare system, the higher price can strengthen rather than weaken adoption.
Theo has earned the right to say that.
He spent 20 years in medtech, beginning at Medtronic in Switzerland, where he learned the fundamentals of product marketing, sales, and business development.
He later moved into startup environments in the US and Europe, and his most prominent operating chapter was at Limflow, where he helped build a company addressing critical limb ischemia for patients facing amputation.
Limflow was acquired by Inari, which was then acquired by Stryker.
Today Theo is co-founder and CEO of Pleo Flow, working with a cardiac surgeon co-founder on a new device in mechanical circulatory support.
What made Theo a super-interesting guest is his clarity and how he separates value creation from value capture in medical devices.
Value creation begins with the patient
Pleo Flow treats cardiogenic shock, where patients deteriorate quickly and current early-stage options are weak. The idea is to use a low-profile device that boosts the effectiveness of an intra-aortic balloon pump, offering a safer early intervention before patients need more invasive support.
But value creation is not enough.
The physician has to find the device easy to use.
It must fit familiar workflows.
It must not require retraining.
And in the US especially, the physician needs to make money from the device.
That brings us to value capture.
Theo’s point is that pricing, reimbursement, and who actually buys the device should shape product development from day one.
This year, his team is focused on three things:
clarifying the FDA pathway,
locking down quality manufacturing, and
getting the technology into patients.
The competitive moat
His moat is not just an innovative device that makes money for surgeons and saves lives for patients.
His moat is the discipline of designing from commercialization backwards.
The Biggest Anti-Pattern in MedTech
Theo’s answer: too many medtech startups begin with a fascinating technology and only later try to figure out the problem, buyer, pricing, reimbursement, and route to market. Instead of starting with the market logic, they start with the invention. He estimates this affects at least 50% and possibly as many as two-thirds of medtech startups
Listen to the show with Theo Mastrokostopoulos here
About me
I’m a pharma-tech founder who learned hard lessons the hard way. Over 22 years, I built five companies: four exits, one glorious flop. Customers ranged from Israeli medical device startups to Verily, Amgen and Walmart.
My latest is an expert-led, agent-operated system called OpenCRO..
Instead of generic cybersecurity playbooks, we identify where your company breaks and build a prioritized, cost-effective cyber and privacy countermeasure plan to reduce your exposure to reputation, revenue, and regulatory risk.
Don’t take my word for it - take the 30 minute stress test.
Your attackers, customers, and competitors are moving faster than you.
In 30 minutes, you’ll see the risks most likely to impact FDA review, procurement, patient safety, and company value.